ArticleEuropean biophysics journal : EBJ2026
Multiscale characterization of lipid bilayer disruption induced by Methyl-β-cyclodextrin (MβCD).
Article in European biophysics journal : EBJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biophysics Austria: from molecular mechanisms to complex biological systems.European biophysics journal : EBJ · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the biophysical impacts of methyl-β-cyclodextrin (MβCD) on supported lipid bilayers composed of DPPC/POPE (1:1) and DPPC/POPE/Chol (1:1:2). Using Quartz Crystal Microbalance with Dissipation (QCM-D), Atomic Force Microscopy (AFM) imaging and force–distance (F–D) curve analysis, we monitored vesicle fusion, assessed bilayer symmetry, and evaluated mechanical stability before and after MβCD treatment. The DPPC/POPE bilayer initially showed a distinct “kink” in its F–D curve and a single breakthrough force, indicating a relatively asymmetric and heterogenous structure. Upon MβCD treatment, the bilayer exhibited symmetry, as evidenced by breakthrough force profiles. Similarly, the cholesterol-containing DPPC/POPE/Chol bilayers displayed two breakthrough points, signifying distinct lipid domains, higher rigidity, and heterogeneity. After one hour of MβCD treatment, these bilayers became more homogeneous and showed a single breakthrough peak—evidence of successful cholesterol or phospholipid extraction. Breakthrough force histograms reinforced these findings by revealing substantial shifts in force distributions. Complementary dynamic light scattering (DLS) and zeta potential measurements confirmed vesicle size and surface charge, while QCM detected notable mass loss in cholesterol-rich bilayers at elevated temperatures. Collectively, these findings underscore the role of cholesterol in bilayer architecture and validate MβCD as an effective modulator of bilayer composition and symmetry.
Indexed as
Identifiers
41609816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.